The Effect of REcombinant Human Thrombopoietin (rhTPO) on Sepsis Patients With aCUte Severe thrombocytopEnia
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether recombinant human thrombopoietin(rhTPO) can
rapidly increase the platelets counts, shorten the time of the platelet returned to normal,
reduce platelet transfusion and bleeding events, prompt recovery of organ function, decrease
the length of ICU stay, and eventually reduce the 28-day mortality in sepsis patients with
severe thrombocytopenia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ruilan Wang
Collaborators:
Changhai Hospital Fudan University Huadong Hospital RenJi Hospital Ruijin Hospital Second Affiliated Hospital of Nanchang University Shanghai Fifth People's Hospital,Fudan University Shanghai Jiao Tong University School of Medicine Shanghai Tongji Hospital, Tongji University School of Medicine Shanghai University of Traditional Chinese Medicine Xinhua Hospital, Shanghai Jiao Tong University School of Medicine